Indeed, Stivarga is a great drug.
The drug, to be sold under the brand name Stivarga, was approved to treat colon cancer that has progressed after prior treatment or that has spread to other parts of the body, the FDA said.
In pivotal clinical trials, Stivarga - known chemically as regorafenib - helped severely ill patients live [OS] on average 1.4 months longer than those who received standard treatment without the Bayer drug.
Stivarga plus standard care also delayed tumor growth [PFS] for an average of two months compared with 1.7 months for standard care alone.
Bayer said Stivarga will be ready for distribution shortly and set a wholesale price for the drug of $9,350 for a 28-day cycle of treatment.
Market Data 
Markets 
AI
